Dark
Light
Today: November 22, 2024
July 30, 2024
1 min read

XYZ Dives into Anduril and Launches New Palantir-Alumni Ventures



TLDR:

– Ross Fubini and XYZ Venture Capital have raised $325 million in funds and added new partners Camille Ricketts and Art Clarke.
– Fubini’s success comes from investing in founders from the Palantir alumni network like Anduril, leading to a $50 million round for Chapter.

Ross Fubini, a backer of early-stage startup Anduril, has raised $325 million in funds at XYZ Venture Capital. Fubini’s success stems from investing in founders from the Palantir alumni network, which has led to impressive gains for the firm, including a $50 million round for Medicare-focused startup Chapter. This success has allowed XYZ to double its partnership to four and hire new partners, Camille Ricketts and Art Clarke. Ricketts, a veteran of work collaboration software unicorn Notion, and Clarke, a leader in AI infrastructure at Apple, bring valuable expertise and experience to the team.

Fubini’s investment strategy of going deeper with select companies has paid off, with Anduril being the firm’s biggest winner to date. With $760 million in assets under management, XYZ is positioning itself to move beyond its public sector and Palantir track record. The firm aims to continue finding the next big thing and remains focused on early-stage investments in a variety of sectors, including defense tech, government procurement, social services, AI, healthcare, and mental health.

While the market for defense tech and government-selling startups is crowded, XYZ maintains an inside track with its expertise in selling to government agencies. The firm has recently invested in several unannounced companies in defense tech, government procurement, and social services. XYZ’s success is attributed to its ability to consistently win deals in the public sector while remaining open to exploring new investment opportunities and industry sectors.


Previous Story

Ex-Twitter Media Head Leads $95M Moxxie Ventures Fundraising Success

Next Story

Investors hungry for supply chain risk tools fuel Altana infusion

Latest from Blog

Go toTop